CORRESP 1 filename1.htm navb20200914_corresp.htm



September 14, 2020





Division of Corporation Finance, Division of Life Sciences

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549



Navidea Biopharmaceuticals, Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-248404) (the “Registration Statement”)

Filed on August 25, 2020


Dear Ladies and Gentlemen:


Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Wednesday, September 16, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.


If you have any questions regarding this request, please contact our outside counsel, Faith Charles of Thompson Hine LLP, at (212) 908-3905 or the undersigned at (614) 793-7500.  Please also call Faith Charles as soon as the Company’s Registration Statement on Form S-3 has been declared effective.  Thank you for your attention to this matter.







By: /s/ Jed A. Latkin

Name: Jed A. Latkin

Title:  Chief Executive Officer, Chief Operating Officer & Chief Financial Officer



cc: Faith Charles, Thompson Hine LLP